# Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular Edema

> **NCT00440609** · PHASE1,PHASE2 · COMPLETED · sponsor: **Philip J. ferrone, M.D.** · enrollment: 50 (actual)

## Conditions studied

- Clinically Significant Diabetic Macular Edema

## Interventions

- **DRUG:** ranibizumab

## Key facts

- **NCT ID:** NCT00440609
- **Lead sponsor:** Philip J. ferrone, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2012-11
- **Final completion:** 2012-12
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2013-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00440609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00440609, "Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular Edema". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00440609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*